Items where authors include "McLaren, D."

Article

Renforth, P., Bellamy, R., Beerling, D. et al. (17 more authors) (2023) Specialty grand challenge: renaming our section to “Carbon Dioxide Removal”. Frontiers in Climate, 5. 1279109. ISSN 2624-9553

Corry, O. orcid.org/0000-0002-7249-0913 and McLaren, D. (2023) "Our way of life is not up for negotiation!": Climate interventions in the shadow of ‘societal security’. Global Studies Quarterly, 3 (3). ksad037. ISSN 2634-3797

Brown, J.E. orcid.org/0000-0003-4960-3032, Royle, K.-L., Gregory, W. et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

James, N., Pirrie, S., Pope, A. et al. (17 more authors) (2016) TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technology Assessment, 20. 53. ISSN 1366-5278

Andronis, L., Goranitis, I., Pirrie, S. et al. (19 more authors) (2016) Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU International. ISSN 1464-4096

Powles, T., Brown, J., Larkin, J. et al. (17 more authors) (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 27 (5). pp. 880-886. ISSN 0923-7534

James, N.D., Pirrie, S.J., Pope, A.M. et al. (19 more authors) (2016) Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both. JAMA Oncology, 2 (4). p. 493. ISSN 2374-2437

Proceedings Paper

Huddart, R., Birtle, A., Cheung, K.C. et al. (19 more authors) (2023) Randomised phase II trial of adaptive image guided bladder radiotherapy: Disease control data. In: Radiotherapy & Oncology. ESTRO 2023, 13-16 May 2023, Vienna, Austria. Elsevier , S704-S705.

Huddart, R., Birtle, A., Cheung, K.C. et al. (19 more authors) (2023) Randomised phase II trial of adaptive image guided bladder radiotherapy: patient reported outcomes. In: Radiotherapy & Oncology. ESTRO 2023, 13-16 May 2023, Vienna, Austria. Elsevier , S331-S332.

Huddart, R.A., Hafeez, S., Omar, A. et al. (17 more authors) (2023) Randomised phase II trial of adaptive image guided radiotherapy in muscle invasive bladder cancer: Late toxicity and cancer outcomes. In: Journal of Clinical Oncology. 2023 ASCO Genitourinary Cancers Symposium, 16-18 Feb 2023. American Society of Clinical Oncology .